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OBJECTIVES This retrospective study was designed to determine the six-month angiographic outcome after
stenting of native coronary arteries in insulin-treated (ITDM) and non-ITDM patients with
diabetes mellitus (DM) and compare the results with those in non-DM patients.
BACKGROUND The influence of the treatment modality for DM on restenosis in patients undergoing
coronary artery stenting has not been elucidated sufficiently.
METHODS A total of 1,439 (70%) of 2,061 patients underwent repeated angiography within six months
of coronary stenting. The ITDM and non-ITDM (oral hypoglycemic drugs or diet) were
documented in 48 (3.3%) and 177 patients (12.3%), respectively, leaving 1,214 non-DM
patients.
RESULTS Baseline reference vessel diameter tended to be smaller in ITDM patients (mean, 2.73 mm)
than in non-DM and non-ITDM patients (2.88 mm and 2.85 mm, respectively). However,
percent diameter stenosis was not different. The median number of stents deployed was 1;
median stent length was 15 mm. Statistically significant differences were present after stenting
for the means of minimal lumen diameter (MLD) and acute gain between ITDM patients
(MLD: 2.67 mm, acute gain: 1.98 mm) and non-DM patients (MLD: 2.81 mm, acute gain:
2.16 mm). At follow-up, percent diameter stenosis, late lumen loss and loss index were
significantly higher in both non-ITDM lesions (42%, 1.14 mm and 0.56, respectively) and
ITDM lesions (48%, 1.26 mm and 0.65, respectively) than in non-DM lesions (35%,
0.96 mm and 0.45, respectively). The corresponding differences between non-ITDM and
ITDM lesions did not reach statistical significance. Restenosis rates in non-DM, non-ITDM
and ITDM lesions were 23.8%, 32.8% (p 5 0.013 vs. non-DM) and 39.6% (p 5 0.02 vs.
non-DM, p 5 0.477 vs. non-ITDM), respectively.
CONCLUSIONS This study showed that compared with stenting in non-DM patients, stenting of native
coronary arteries in DM patients is associated with significantly increased lumen renarrowing,
regardless of the treatment modality for DM. (J Am Coll Cardiol 2000;35:1554–9) © 2000
by the American College of Cardiology
Diabetes mellitus (DM) is a risk factor for a variety of
vascular disease states that are ultimately the primary causes
of morbidity and mortality in DM patients. The increased
propensity for atherosclerosis predisposes DM patients to
stroke as well as acute and chronic coronary syndromes.
Balloon angioplasty to treat coronary artery disease in
patients with DM has been associated with an increased rate
of acute complications and a lower long-term success rate
compared with non-DM patients (1–4). The randomized
Bypass Angioplasty Revascularization Investigation trial
comparing clinical outcomes after balloon angioplasty versus
coronary artery bypass grafting in patients with multivessel
disease revealed that DM patients randomized to the
angioplasty arm exhibited a higher coronary morbidity and
mortality than non-DM patients (2). It has therefore been
suggested that multivessel balloon angioplasty should be
abandoned in DM patients (5,6).
To date, conflicting data have been published regarding
the long-term outcomes after coronary stent placement in
DM patients. While Van Belle et al. (7) found no difference
in the restenosis rates between DM and non-DM patients,
Kastrati et al. (8) reported a significantly higher late lumen
loss and an increased risk for restenosis in the former group
of patients. In a recent study distinguishing insulin-treated
(ITDM) from non–insulin-treated (non-ITDM) diabetic
patients, Abizaid et al. (9) observed an increased target
lesion revascularization (TLR) rate versus non-DM patients
only in ITDM but not in non-ITDM patients. Repeated
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angiography to determine restenosis rates had not been
performed in that study. It was therefore the purpose of the
present study to assess angiographic restenosis after coro-
nary stenting in both ITDM and non-ITDM patients and
compare the results in either group with those in non-DM
patients.
METHODS
Patients. From July 1, 1994, until January 1, 1997, 2,061
consecutive patients, among them 313 with documented
DM, underwent stent implantation in native coronary artery
lesions at our institution. Angiographic follow-up within six
months was obtained from 1,439 patients (70%) who
comprised the study group. Diabetes mellitus was present in
225 (15%) of the 1,439 patients; 48 DM patients were
treated with insulin, whereas the 177 non-ITDM patients
either took hypoglycemic drugs (n 5 100) or adhered to a
strict diet such that their fasting blood glucose level was
maintained at ,140 mg/dl. Pertinent patient characteristics
for the three patient subgroups are given in Table 1.
Compared with non-DM patients, DM patients were more
often female, were slightly older and more often hyperten-
sive. The prevalence of single-vessel versus multivessel
coronary artery disease was equally distributed in the three
patient groups.
Coronary intervention. The patients were informed about
the coronary interventional procedure and gave their written
consent. Stent implantation was performed routinely after
recanalization of a total occlusion and in nonoccluded
lesions if the following criteria were met: 1) a suboptimal
result of balloon angioplasty (residual stenosis .20% or
major dissection) or 2) a bail-out situation. During the
procedure, a total of 10,000 to 15,000 U of heparin were
given as a bolus injection. Balloon angioplasty utilized the
monorail system after passage of the lesions with a guide
wire. High-pressure stent implantation using noncompliant
balloons was angiographically guided. A visually estimated
residual diameter stenosis of ,10% was aimed at. Patients
were discharged from the hospital on a combination regi-
men of 100 mg/d of acetylsalicylic acid and 500 mg/d of
ticlopidine for four to 12 weeks; they were scheduled for a
repeat angiography after six months.
Quantitative coronary angiography. Angiographic vari-
ables obtained for every patient included the lesion length
(length of vessel segment visually stenotic by at least 50%),
the reference vessel diameters proximal and distal to the
lesion and the minimal lumen diameter (MLD). Measure-
ments were taken in identical, “worst view” projections
using a hand-held digital caliper on optically magnified
images. The diameter of the guiding catheter served as
angiographic reference. Proximal and distal reference vessel
diameters were averaged to obtain a mean reference vessel
diameter.
The primary end point of the study was restenosis at
follow-up, defined as a diameter stenosis of $50%.
Definitions of derived angiographic variables. Defini-
tions are as follows: acute gain 5 MLD poststenting minus
MLD at baseline; relative gain 5 acute gain divided by
reference vessel diameter; late lumen loss 5 MLD post-
stenting minus MLD at follow-up; and loss index 5 late
lumen loss divided by acute gain.
Definition of myocardial infarction. Myocardial infarc-
tion was classified as the development of new pathologic Q
Abbreviations and Acronyms
DM 5 diabetes mellitus
ITDM 5 insulin-treated diabetes mellitus
MLD 5 minimal lumen diameter
TLR 5 target lesion revascularization
Table 1. Demographic Patient Data
Non-DM Non-ITDM ITDM p Value
No. of patients 1,214 177 48
Male gender 998 (82%) 136 (77%) 34 (71%) 0.041
Age (yr) 59 6 9 62 6 9 60 6 9 0.010
Hyperlipidemia 867 (71%) 128 (72%) 31 (65%) 0.561
Hypertension 689 (57%) 132 (75%) 35 (73%) ,0.0001
Smoking 0.073
Current 316 (26%) 35 (20%) 6 (13%)
Ex 376 (31%) 60 (34%) 16 (33%)
Coronary artery disease 0.180
1 vessel 545 (45%) 71 (40%) 23 (40%)
2 vessels 466 (38%) 64 (36%) 15 (31%)
3 vessels 203 (17%) 42 (24%) 10 (21%)
Prior CABG 153 (13%) 30 (17%) 5 (10%) 0.237
Prior myocardial infarction 490 (40%) 67 (38%) 24 (50%) 0.314
CABG 5 coronary artery bypass grafting; DM 5 diabetes mellitus; ITDM 5 insulin-treated diabetes mellitus.
1555JACC Vol. 35, No. 6, 2000 Schofer et al.
May 2000:1554–9 Coronary Stenting in Diabetes Mellitus
waves in two or more contiguous leads and/or elevation of
postprocedure creatine kinase levels to more than two times
normal.
Statistics. In patients with multiple coronary lesions, only a
single lesion, chosen at random, was entered into the
analysis.
Continuous variables are presented as mean 6 1 SD,
where appropriate. In case of a non-Gaussian distribution,
median and range are given. Group differences among
normally distributed continuous variables were assessed
utilizing analysis of variance with Bonferroni’s correction;
not normally distributed continuous variables were tested
using the Kruskal-Wallis and Mann-Whitney U tests.
Nominal variables were analyzed with the chi-square test.
Statistical significance was assumed at p values ,0.05;
whenever three between-group comparisons were made,
statistical significance was assumed at a p value ,0.05/3 5
0.0167 (Bonferroni’s correction).
RESULTS
Procedural results. Following the definition of acute pro-
cedural success as a ,10% residual stenosis without major
adverse cardiac events during hospitalization and/or sub-
acute stent thrombosis, the procedure was successful in 964
non-DM patients (79%), 138 non-ITDM patients (78%)
and 41 ITDM patients (85%) (p 5 0.526). Myocardial
infarctions during hospitalization occurred in 13 patients (9
non-DM and 4 non-ITDM patients, p 5 0.109); in 2 of the
9 non-DM patients, subacute stent thrombosis was ob-
served.
Target vessel distribution was statistically not different in
the three patient groups; on average, the left anterior
Table 2. Angiographic and Procedural Patient Data
Non-DM Non-ITDM ITDM p Value
No. of lesions 1,214 177 48
Target vessel distribution 0.335
Left main 2 (0.2%) 0 (0%) 0 (0%)
LAD 532 (44%) 83 (47%) 23 (48%)
RCA 420 (35%) 64 (36%) 12 (25%)
LCx 260 (21%) 30 (17%) 13 (27%)
Baseline
Lesion length (mm)* 8.2 (0.8–59.8) 8.1 (1.3–41.2) 7.1 (2.7–72.9) 0.921
Reference vessel diameter (mm) 2.88 6 0.44 2.85 6 0.45 2.73 6 0.51 0.050
Minimal lumen diameter (mm) 0.65 6 0.40 0.66 6 0.37 0.69 6 0.43 0.790
Diameter stenosis (%) 77 6 14 77 6 13 75 6 14 0.374
After stenting
Stent types per lesion 0.378
Palmaz-Schatz (J&J) only 352 (29%) 46 (26%) 11 (23%)
Microstent (AVE) only 516 (42%) 72 (41%) 25 (52%)
MultiLink (ACS) only 162 (13%) 30 (17%) 5 (10%)
Others/combinations 184 (15%) 29 (16%) 7 (15%)
Stents per lesion*† 1 (0.5–4.5) 1 (0.5–5) 1 (0.5–4) 0.719
Stented vessel segment length (mm)* 15 (4–78) 15 (4–78) 16 (6–66) 0.902
Balloon/vessel diameter ratio 1.13 6 0.17 1.14 6 0.14 1.14 6 0.17 0.929
Minimal lumen diameter (mm) 2.81 6 0.37 2.76 6 0.40 2.67 6 0.47 0.015
Diameter stenosis (%) 1 6 12 2 6 13 0 6 13 0.574
Acute gain (mm) 2.16 6 0.49 2.10 6 0.48 1.98 6 0.53 0.014
Relative gain 0.76 6 0.17 0.75 6 0.18 0.73 6 0.18 0.498
At follow-up
Follow-up period (mo) 5.4 6 1.9 5.4 6 2.2 5.7 6 2.1 0.423
Reference vessel diameter (mm) 2.81 6 0.48 2.79 6 0.47 2.62 6 0.49 0.028
Minimal lumen diameter (mm) 1.85 6 0.76 1.64 6 0.81 1.43 6 0.82 ,0.0001
Diameter stenosis (%) 35 6 24 41 6 26 47 6 27 ,0.0001
Late lumen loss (mm) 0.96 6 0.72 1.12 6 0.73 1.25 6 0.83 0.0015
Loss index 0.45 6 0.34 0.54 6 0.35 0.64 6 0.42 ,0.0001
Restenotic lesions 289 (23.8%) 58 (32.8%) 19 (39.6%) 0.003
Reoccluded lesions 32 (2.6%) 11 (6.2%) 5 (10.4%) 0.0009
Target lesion revascularizations 211 (17.4%) 39 (22.0%) 14 (29.2%) 0.047
*Median. †“Half” stent: #9 mm.
ACS 5 Advanced Cardiovascular Systems, Inc.; AVE 5 Arterial Vascular Engineering, Inc.; J&J 5 Johnson & Johnson Interventional Systems; LAD 5 left anterior
descending coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery.
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descending coronary artery was affected in 44% of lesions,
the right coronary artery in 34% and the left circumflex
coronary artery in 21% (Table 2).
Stenting was performed as a bail-out measure in a total of
10 patients, 9 of whom were non-DM patients and 1 who
took hypoglycemic drugs (p 5 0.828). Adjunctive debulking
devices such as the rotablator (n 5 48) or the laser catheter
(n 5 15) were used in 63 patients, 47 of whom were
non-DM patients, 14 belonged to the non-ITDM group
(10 oral, 4 diet), and 2 were treated with insulin (p 5
0.049). The median number of stents deployed per lesion
was 1 in all groups, ranging from 0.5 (i.e., a “half” stent of
#9 mm in length) to 5.0, and the median stented vessel
segment length was 15 mm. The median smallest stent
diameter used was 3.0 mm in all groups; smallest stent
diameter ranged from 2.0 to 4.5 mm in the non-DM group,
from 2.5 to 4.0 mm in the non-ITDM group and from 2.5
to 3.5 mm in the ITDM group (p 5 0.087). No difference
between patient groups was present in the distribution of
stent types (Table 2).
Angiographic analyses. The median lengths of non-DM
lesions, non-ITDM lesions and ITDM lesions were
8.5 mm, 8.0 mm and 7.1 mm, respectively (Table 2); these
differences were statistically not significant. At baseline, the
mean reference vessel diameter in ITDM lesions (2.73 mm)
was found to be less than in both non-DM lesions
(2.88 mm, p 5 0.021) and non-ITDM lesions (2.85 mm,
p 5 0.109). The mean MLD in ITDM lesions (0.69 mm)
was slightly increased, though not significantly so, over that
in non-ITDM (0.66 mm) and non-DM lesions (0.65 mm).
Mean percent diameter stenosis was not different in the
three groups.
Mean MLD after stenting in ITDM lesions, but not in
non-ITDM lesions, was significantly less than in non-DM
lesions (corresponding to a significantly lower acute gain);
the means of relative gain and diameter stenosis were not
different between groups.
At follow-up, the means of diameter stenosis (35%), late
lumen loss (0.96 mm) and loss index (0.45) were all
significantly less in non-DM lesions compared with both
non-ITDM lesions (41% [p 5 0.0006], 1.12 mm [p 5
0.009] and 0.54 [p 5 0.002], respectively) and ITDM
lesions (47% [p 5 0.0007], 1.25 mm [p 5 0.008] and 0.64
[p 5 0.0002], respectively) (Fig. 1 and 2). Consequently,
the restenosis rates were increased in DM lesions, but the
difference versus non-DM lesions was statistically signifi-
cant only for non-ITDM lesions (Fig. 3). Differences
between non-ITDM and ITDM lesions did not reach
statistical significance for any angiographic variable ob-
tained at follow-up.
The prevalences of TLR in the three patient groups were
17.4% (non-DM), 22.0% (non-ITDM) and 29.2%
(ITDM), with an overall p value of 0.047 but no statistical
significance between groups.
DISCUSSION
Main findings. This study sought to assess the long-term
angiographic outcome after stent placement in native coro-
nary arteries in diabetic versus nondiabetic patients. The
former were distinguished into two groups with regard to
the treatment modality for DM, that is, patients were either
treated with insulin or not. Reference vessel diameter was
smallest in the ITDM group of patients, yet target vessel
distribution, lesion length and percent diameter stenosis
were statistically not different in the three groups. Lesions
were supplied with a median of one 15-mm stent, resulting
in identical mean residual stenoses after the intervention but
a significantly lower MLD (vs. non-DM lesions) in ITDM
lesions. At follow-up, mean diameter stenosis, late lumen
Figure 1. Cumulative frequency distributions of percent diameter
stenosis at follow-up for lesions in non-DM, non-ITDM and
ITDM patients. Statistically significant differences are present
between the non-DM distribution and either DM distribution,
but not between the DM distributions.
Figure 2. Cumulative frequency distributions of late lumen loss for
lesions in non-DM, non-ITDM and ITDM patients. Statistically
significant differences are present between the non-DM distribu-
tion and either DM distribution, but not between the DM
distributions.
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loss and loss index were significantly increased in both
ITDM and non-ITDM lesions compared with non-DM
lesions; mean values for these variables were highest in the
ITDM subgroup, but statistical significance versus the
non-ITDM subgroup was not reached for any parameter.
Consequently, the restenosis rate in non-ITDM lesions
(32.8%) as well as in ITDM lesions (39.6%) was higher than
in non-DM lesions (23.8%), yet statistically significantly so
only for non-ITDM lesions.
Previous studies. Our findings support recent studies re-
porting an adverse outcome after stent placement in native
coronary arteries for DM compared with non-DM patients
(8,10). Lau et al. (10) studied 42 DM patients and an equal
number of non-DM patients matched for stent design,
reference vessel and stent diameter, target vessel treated and
residual diameter stenosis after stenting; the restenosis rate
in DM patients was 40.5%, significantly higher than in
non-DM patients (16.7%). This study is in concordance
with a recent analysis of predictive factors of restenosis after
coronary stent placement in 1,084 patients which revealed
that the presence of DM increased the risk for restenosis by
a factor of 1.86 (8). In neither study was a distinction made
between DM patients treated with insulin and those either
taking oral hypoglycemic drugs or adhering to a diet.
This distinction has been made by Abizaid et al. (9) who
investigated the clinical outcomes after coronary stenting in
954 consecutive patients. There were 151 non-ITDM
patients and 97 ITDM patients. Target lesion revascular-
ization was significantly increased in the latter patients (28%
vs. 16.3% in non-DM patients), whereas no statistically
significant difference versus non-DM patients was observed
in this variable for non-ITDM patients (17.6%). However,
the rate of angiographic follow-up in the different subgroups
has not been reported. To our knowledge, no study to date
has addressed the angiographic outcome after stenting in
DM patients differentiated by treatment modality. In our
study, the rates of angiographic follow-up in the three
subgroups were not different. Late lumen loss as a measure
of neointimal hyperplasia was significantly increased in
non-ITDM and ITDM lesions (by 15% and 27%, respec-
tively) compared with non-DM lesions. Although late
lumen loss was higher in ITDM lesions than in non-ITDM
lesions, this difference was statistically not significant. Tar-
get lesion revascularization based on the findings at
follow-up angiography was increased in both non-ITDM
and ITDM patients compared with non-DM patients, but
statistical significance was not reached. Thus, the bottom
line of our study is that patients with DM, regardless of the
treatment modality for DM, exhibit a markedly higher
propensity for neointimal hyperplasia after stenting of native
coronary arteries than do patients without DM.
Mechanisms. With the lack of elastic recoil and constric-
tive vascular remodeling in stented coronary lesions, neoin-
timal hyperplasia secondary to smooth muscle proliferation
constitutes the major mechanism responsible for lumen
renarrowing after coronary stenting (11,12). Several in vitro
and animal studies have supported the hypothesis that the
mechanisms underlying smooth muscle cell proliferation are
affected by the presence of DM (13). Serum from DM
patients enhances smooth muscle cell proliferation to a
higher degree than does serum of non-DM patients, indi-
cating a difference in the concentration of growth promot-
ing factors (14). An increased glucose concentration has
been shown to result in an increased expression of the basic
fibroblast growth factor, the transforming growth factor-
alpha and the receptor for platelet-derived growth factor-
beta in smooth muscle cells (15–17). High insulin levels
stimulate the expression of endothelin-1 in endothelial cells
and potentiate the effect of the insulin-like growth factor-1
on smooth muscle cells (18–20). Finally, in DM patients,
local thrombus formation after stenting may be enhanced as
a consequence of increased platelet reactivity, an impaired
thrombolytic system and higher blood levels of clotting
factors (21–24). Another factor predisposing to the high
restenosis rate in ITDM lesions may be the significantly
smaller poststenting MLD (25).
Study limitations. This was a retrospective study with all the
inherent shortcomings of such a study design. The small
number of ITDM patients may have given rise to type II
statistical errors relative to the comparisons with non-DM
patients. If the absolute difference in restenosis rates between
non-ITDM and ITDM patients of 6.8% (corresponding to a
21% relative increase) was to be accepted or rejected with a
statistical power of 80% and a type I error of 5%, approximately
785 patients would be needed in each group. The impact of
metabolic parameters such as insulin and C-peptide levels as
well as the concentrations of glucose and advanced glycoliza-
tion end products has not been assessed.
CONCLUSIONS
This study showed that, compared with stenting in nondi-
abetic patients, stenting of native coronary arteries in
Figure 3. Restenosis rates for lesions in non-DM, non-ITDM and
ITDM patients.
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diabetic patients is associated with an increased propensity
for neointimal hyperplasia, regardless of the treatment
modality for diabetes. In particular, this finding holds true
for diabetic patients who are not treated with insulin.
Reprint requests and correspondence: Dr. Joachim Schofer,
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